Immunogen Inc. Message Board
-
Was is das IMGN289???
New IMGN wholly owned compound to be discussed at the next company presentation.
-
IMGN289 presumably Immunogen's first ADC with a pyrrolobenzodiazepine as cytotoxic agent (intercalator of DNA, induces in dividing cells cell cycle stop in G0/G1 followed by apoptosis).
Search for Immunogen's patent application number 20120244171Sentiment: Strong Buy
- 1 Reply to mt_cervin
-
... herewith, IMGN's first alternative to its maytansinoid-type of antitubulin agents that would enter the clinics this year - my guesstimate.
IMGN's competitors are Roche/Genentech vs. Seattle Genetics, both of them equipped with PBDs from Spirogen.Sentiment: Strong Buy
-
From IV, this could dwarf TDM1
- 2 Replies to atomsmith
-
Hard to tell if killing some B-cells is really a good way for autoimmune diseases. Keep the excited immune system on check, yes, but...
-
far too early to tell, but autoimmune is a new area for IMGN and a very large market. Looking forward to hearing about preclinical testing results and plans for clinical development. On the + side, autoimmune trials do not take years to complete. On the - side competition is stiff and side effects are less tolerable for most autoimmune indications compared to onclolgy. If early results are good, many companies will want to partner and in 1-2 years, this could become a primary value driver. They will need to hire some people with a different skill set, but have VRTX in the area from which to draw.
-